323 related articles for article (PubMed ID: 32605175)
1. Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors.
Hagerty BL; Pegna GJ; Xu J; Tai CH; Alewine C
Biomolecules; 2020 Jun; 10(7):. PubMed ID: 32605175
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
Hassan R; Alewine C; Mian I; Spreafico A; Siu LL; Gomez-Roca C; Delord JP; Italiano A; Lassen U; Soria JC; Bahleda R; Thomas A; Steinberg SM; Peer CJ; Figg WD; Niederfellner G; Méresse Naegelen V; Pastan I
Cancer; 2020 Nov; 126(22):4936-4947. PubMed ID: 32870522
[TBL] [Abstract][Full Text] [Related]
3. Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.
Awuah P; Bera TK; Folivi M; Chertov O; Pastan I
Mol Cancer Ther; 2016 Jul; 15(7):1648-55. PubMed ID: 27196771
[TBL] [Abstract][Full Text] [Related]
4. An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models.
Scales SJ; Gupta N; Pacheco G; Firestein R; French DM; Koeppen H; Rangell L; Barry-Hamilton V; Luis E; Chuh J; Zhang Y; Ingle GS; Fourie-O'Donohue A; Kozak KR; Ross S; Dennis MS; Spencer SD
Mol Cancer Ther; 2014 Nov; 13(11):2630-40. PubMed ID: 25249555
[TBL] [Abstract][Full Text] [Related]
5. Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Hagemann UB; Ellingsen C; Schuhmacher J; Kristian A; Mobergslien A; Cruciani V; Wickstroem K; Schatz CA; Kneip C; Golfier S; Smeets R; Uran S; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Mumberg D; Ziegelbauer K; Cuthbertson AS
Clin Cancer Res; 2019 Aug; 25(15):4723-4734. PubMed ID: 31064781
[TBL] [Abstract][Full Text] [Related]
6. Discovery of mesothelin and exploiting it as a target for immunotherapy.
Pastan I; Hassan R
Cancer Res; 2014 Jun; 74(11):2907-12. PubMed ID: 24824231
[TBL] [Abstract][Full Text] [Related]
7. Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
Cerise A; Bera TK; Liu X; Wei J; Pastan I
Clin Colorectal Cancer; 2019 Sep; 18(3):192-199.e1. PubMed ID: 31345777
[TBL] [Abstract][Full Text] [Related]
8. Eradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody-drug conjugates from synthetic antibody libraries.
Hsu HJ; Tung CP; Yu CM; Chen CY; Chen HS; Huang YC; Tsai PH; Lin SI; Peng HP; Chiu YK; Tsou YL; Kuo WY; Jian JW; Hung FH; Hsieh CY; Hsiao M; Chuang SS; Shen CN; Wang YA; Yang AS
Sci Rep; 2021 Jul; 11(1):15430. PubMed ID: 34326410
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
Oncotarget; 2017 Apr; 8(16):26744-26754. PubMed ID: 28460459
[TBL] [Abstract][Full Text] [Related]
10. Mesothelin-targeted agents in clinical trials and in preclinical development.
Kelly RJ; Sharon E; Pastan I; Hassan R
Mol Cancer Ther; 2012 Mar; 11(3):517-25. PubMed ID: 22351743
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding.
Zhang Y; Chertov O; Zhang J; Hassan R; Pastan I
Cancer Res; 2011 Sep; 71(17):5915-22. PubMed ID: 21775520
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
Hassan R; Bullock S; Premkumar A; Kreitman RJ; Kindler H; Willingham MC; Pastan I
Clin Cancer Res; 2007 Sep; 13(17):5144-9. PubMed ID: 17785569
[TBL] [Abstract][Full Text] [Related]
13. New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma.
Zhang YF; Phung Y; Gao W; Kawa S; Hassan R; Pastan I; Ho M
Sci Rep; 2015 May; 5():9928. PubMed ID: 25996440
[TBL] [Abstract][Full Text] [Related]
14. Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.
Filpula D; Yang K; Basu A; Hassan R; Xiang L; Zhang Z; Wang M; Wang QC; Ho M; Beers R; Zhao H; Peng P; Zhou J; Li X; Petti G; Janjua A; Liu J; Wu D; Yu D; Zhang Z; Longley C; FitzGerald D; Kreitman RJ; Pastan I
Bioconjug Chem; 2007; 18(3):773-84. PubMed ID: 17346030
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.
Alewine C; Xiang L; Yamori T; Niederfellner G; Bosslet K; Pastan I
Mol Cancer Ther; 2014 Nov; 13(11):2653-61. PubMed ID: 25239937
[TBL] [Abstract][Full Text] [Related]
16. Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models.
Jiang Q; Ghafoor A; Mian I; Rathkey D; Thomas A; Alewine C; Sengupta M; Ahlman MA; Zhang J; Morrow B; Steinberg SM; Pastan I; Hassan R
Sci Transl Med; 2020 Jul; 12(550):. PubMed ID: 32611684
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
Li Q; Verschraegen CF; Mendoza J; Hassan R
Anticancer Res; 2004; 24(3a):1327-35. PubMed ID: 15274292
[TBL] [Abstract][Full Text] [Related]
18. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.
Weldon JE; Xiang L; Zhang J; Beers R; Walker DA; Onda M; Hassan R; Pastan I
Mol Cancer Ther; 2013 Jan; 12(1):48-57. PubMed ID: 23136186
[TBL] [Abstract][Full Text] [Related]
19. Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy.
Bera TK; Liu W; Leshem J; King E; Kozlov S; Pastan I
J Immunother; 2019 May; 42(4):119-125. PubMed ID: 30933045
[TBL] [Abstract][Full Text] [Related]
20. The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy.
Xiang X; Phung Y; Feng M; Nagashima K; Zhang J; Broaddus VC; Hassan R; Fitzgerald D; Ho M
PLoS One; 2011 Jan; 6(1):e14640. PubMed ID: 21305058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]